Advertisement
Canada markets closed

  • S&P/TSX

    21,807.37
    +98.93 (+0.46%)
     

  • S&P 500

    4,967.23
    -43.89 (-0.88%)
     

  • DOW

    37,986.40
    +211.02 (+0.56%)
     

  • CAD/USD

    0.7275
    +0.0012 (+0.16%)
     

  • CRUDE OIL

    83.24
    +0.51 (+0.62%)
     

  • Bitcoin CAD

    87,447.75
    +824.17 (+0.95%)
     

  • CMC Crypto 200

    1,374.85
    +62.23 (+4.74%)
     

  • GOLD FUTURES

    2,406.70
    +8.70 (+0.36%)
     

  • RUSSELL 2000

    1,947.66
    +4.70 (+0.24%)
     

  • 10-Yr Bond

    4.6150
    -0.0320 (-0.69%)
     

  • NASDAQ

    15,282.01
    -319.49 (-2.05%)
     

  • VOLATILITY

    18.71
    +0.71 (+3.94%)
     

  • FTSE

    7,895.85
    +18.80 (+0.24%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • CAD/EUR

    0.6824
    +0.0003 (+0.04%)
     

Company News For Oct 5, 2017

Tirthankar Chakraborty
Updated
CWCO vs. GWRS: Which Stock Is the Better Value Option?

  • Shares of Pepsico, Inc. PEP gained 0.2% after reporting third quarter 2017 earnings per share of $1.48, surpassing the Zacks Consensus Estimate of $1.43

  • Mattel, Inc.’s MAT shares surged 0.3% after the company announced Joseph Euteneuer as its new Chief Financial Officer

  • Shares of Mylan N.V. MYL rallied 16.2% after the company announced that it had received an approval from Food and Drug Administration for the generic version of multiple sclerosis treatment drug – Copaxone, made by Teva Pharmaceutical Industries Ltd. (TEVA)

  • Office Depot, Inc.’s ODP shares plummeted 17.7% after the company lowered its revenue guidance for 2017 to $400 million — $425 million from $500 million initially


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Pepsico, Inc. (PEP) : Free Stock Analysis Report
 
Mylan N.V. (MYL) : Free Stock Analysis Report
 
Office Depot, Inc. (ODP) : Free Stock Analysis Report
 
Mattel, Inc. (MAT) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research